Valuation: PolyPid Ltd.

Market Cap 102M 89.43M 82.42M 76.39M 145M 9.7B 147M 988M 384M 4.79B 384M 375M 16.55B P/E 2026 *
-3.73x
P/E 2027 * -4.25x
Enterprise Value 102M 89.43M 82.42M 76.39M 145M 9.7B 147M 988M 384M 4.79B 384M 375M 16.55B EV / Sales 2026 *
-
EV / Sales 2027 * 7.47x
Free-Float
78.77%
Yield 2026 *
-
Yield 2027 * -
1 day-4.48%
1 week+4.92%
Current month+4.92%
1 month+18.44%
3 months+29.37%
6 months+11.74%
Current year+22.81%
1 week 4.95
Extreme 4.95
5.62
1 month 4.44
Extreme 4.44
5.62
Current year 4.01
Extreme 4.01
5.62
1 year 3.06
Extreme 3.06
5.62
3 years 2.3
Extreme 2.3
12.27
5 years 2.3
Extreme 2.3
289.2
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 2022-06-30
Director of Finance/CFO 39 -
Chief Operating Officer 48 2021-12-31
Director TitleAgeSince
Director/Board Member 75 2020-05-31
Director/Board Member 74 2018-11-30
Director/Board Member 84 2008-03-31
Date Insider Type Main position Quantity % Market Cap.
03-17Other

Director

21,565 0.1130%
03-17Other

Chief Operating Officer

159,394 0.8353%
03-17Other

Director

24,623 0.1290%
Change 5-day change 1-year change 3-year change Capi.($)
-4.48%+4.92%+54.49%-56.44% 107M
+2.96%+3.01%+59.87%+173.31% 1,070B
+3.05%+5.23%+72.11%+67.81% 624B
-0.04%+1.20%+35.72%+87.93% 450B
-2.58%-2.07%+27.62%+22.57% 328B
+1.36%+0.17%+29.90%+49.33% 284B
+1.98%+4.08%-25.78%-39.02% 217B
+0.45%+1.65%+25.65%+68.35% 198B
+5.21%+7.93%+21.99%+83.23% 161B
+1.48%-0.04%-4.64%-32.25% 135B
Average +0.32%+2.71%+29.69%+42.48% 346.76B
Weighted average by Cap. +1.50%+1.63%+41.85%+87.34%

Financials

2026 *2027 *
Net sales - 13.68M 11.97M 11.03M 10.22M 19.41M 1.3B 19.72M 132M 51.43M 641M 51.34M 50.23M 2.21B
Net income -33.91M -29.68M -27.35M -25.35M -48.12M -3.22B -48.9M -328M -128M -1.59B -127M -125M -5.49B -32.76M -28.67M -26.42M -24.49M -46.49M -3.11B -47.24M -317M -123M -1.53B -123M -120M -5.3B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change Volume
26-07-07 US$5.330 -4.48% 189,764
26-07-06 US$5.580 +11.16% 504,200
26-07-02 US$5.020 -0.59% 223,851
26-07-01 US$5.050 -0.59% 188,608
26-06-30 US$5.080 +2.21% 283,620
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.330USD
Average target price
12.25USD
Spread / Average Target
+129.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock